X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (51) 51
index medicus (42) 42
male (39) 39
female (37) 37
oncology (37) 37
middle aged (31) 31
adult (28) 28
aged (27) 27
pharmacology & pharmacy (18) 18
medicine & public health (17) 17
cancer (15) 15
aged, 80 and over (14) 14
neoplasms - drug therapy (14) 14
niacinamide - analogs & derivatives (14) 14
pharmacology/toxicology (14) 14
treatment outcome (12) 12
antineoplastic agents - therapeutic use (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
care and treatment (10) 10
phenylurea compounds (10) 10
research (10) 10
retrospective studies (10) 10
bevacizumab (9) 9
chemotherapy (9) 9
antineoplastic agents - adverse effects (8) 8
pharmacology (8) 8
sorafenib (8) 8
antitumor-activity (7) 7
benzenesulfonates - adverse effects (7) 7
carcinoma, hepatocellular - drug therapy (7) 7
gastroenterology & hepatology (7) 7
gastroenterology and hepatology (7) 7
hypertension (7) 7
pharmacokinetics (7) 7
pyridines - adverse effects (7) 7
studies (7) 7
tumors (7) 7
vascular endothelial growth factor (7) 7
angiogenesis inhibitors (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
benzenesulfonates - therapeutic use (6) 6
disease progression (6) 6
drug administration schedule (6) 6
drug therapy (6) 6
endothelial growth-factor (6) 6
liver neoplasms - drug therapy (6) 6
lung neoplasms - drug therapy (6) 6
organoplatinum compounds - administration & dosage (6) 6
oxaliplatin (6) 6
phase-i (6) 6
pyridines - therapeutic use (6) 6
survival analysis (6) 6
therapy (6) 6
toxicity (6) 6
vascular endothelial growth factor a - antagonists & inhibitors (6) 6
young adult (6) 6
angiogenesis (5) 5
angiogenesis inhibitors - adverse effects (5) 5
antineoplastic agents - blood (5) 5
cancer therapies (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
cisplatin (5) 5
disease-free survival (5) 5
dose-response relationship, drug (5) 5
hypertension - chemically induced (5) 5
medical research (5) 5
medicine, experimental (5) 5
patients (5) 5
phase-ii (5) 5
reproducibility of results (5) 5
sunitinib (5) 5
tyrosine (5) 5
vegf-a (5) 5
abridged index medicus (4) 4
adolescent (4) 4
analysis (4) 4
angiogenesis inhibitors - therapeutic use (4) 4
animals (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - pharmacokinetics (4) 4
bay-43-9006 (4) 4
benzenesulfonates - blood (4) 4
benzenesulfonates - pharmacokinetics (4) 4
carcinoma, hepatocellular - pathology (4) 4
cell lung-cancer (4) 4
clinical trials (4) 4
colorectal-cancer (4) 4
combination (4) 4
gemcitabine (4) 4
health aspects (4) 4
hematology, oncology and palliative medicine (4) 4
hepatocellular carcinoma (4) 4
indoles - therapeutic use (4) 4
inhibitor drugs (4) 4
liver cancer (4) 4
liver neoplasms - pathology (4) 4
lung cancer, non-small cell (4) 4
prognosis (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, p. e37563
Background: Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated... 
SKELETAL-MUSCLE | CANCER-PATIENTS | MULTIDISCIPLINARY SCIENCES | VALIDATION | BODY-COMPOSITION | INHIBITOR | PHASE-I | Niacinamide - analogs & derivatives | Humans | Middle Aged | Liver Neoplasms - drug therapy | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Sarcopenia - chemically induced | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Liver Neoplasms - metabolism | Survival Analysis | Adult | Aged | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Carcinoma, Hepatocellular - metabolism | Pyridines - therapeutic use | Antimitotic agents | Medical research | Sarcopenia | Analysis | Diarrhea | Medicine, Experimental | Hepatoma | Antineoplastic agents | Liver cirrhosis | Nuclear magnetic resonance--NMR | Laboratories | Toxicity | Oncology | Hepatocellular carcinoma | Males | Body composition | Body mass index | Liver cancer | Angiogenesis | Toxicology | Computed tomography | Tomography | Nosocomial infections | Drug dosages | Teaching hospitals | Hypertension | Medical imaging | Pharmacology | Metabolism | Patients | Constraining | Feet | Musculoskeletal system | Clinical medicine | Pharmacokinetics | Tumors | Nuclear magnetic resonance | NMR
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 2, p. e16978
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in... 
ADVANCED HEPATOCELLULAR-CARCINOMA | AZYGOS BLOOD-FLOW | BIOLOGY | TUMOR | PHASE-II | INVIVO VALIDATION | GROWTH-FACTOR | HYPERDYNAMIC SPLANCHNIC CIRCULATION | HYPERTENSIVE-RATS | RAF/MEK/ERK PATHWAY | VARICEAL HEMORRHAGE | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Hypertension, Portal - physiopathology | Humans | Middle Aged | Liver Neoplasms - complications | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Benzenesulfonates - adverse effects | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Hypertension, Portal - etiology | Regional Blood Flow - drug effects | Carcinoma, Hepatocellular - complications | Antineoplastic Agents - adverse effects | Adult | Female | Liver Neoplasms - pathology | Pyridines - therapeutic use | Liver Cirrhosis - drug therapy | Portal Vein - drug effects | Liver Cirrhosis - complications | Liver Neoplasms - drug therapy | Magnetic Resonance Angiography | Disease Progression | Hypertension, Portal - drug therapy | Portal Vein - physiology | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Liver Cirrhosis - physiopathology | Hypertension | Antimitotic agents | Tyrosine | Complications and side effects | Liver | Antineoplastic agents | Liver cirrhosis | Therapy | Oxidative stress | Nuclear magnetic resonance--NMR | Clinical trials | Oncology | Hepatocellular carcinoma | Collateral | Metastasis | Hemorrhage | Beta blockers | Liver cancer | Angiogenesis | Rodents | Aorta | Vascular endothelial growth factor | Drug dosages | Protein-tyrosine kinase | Liver diseases | Magnetic resonance | Patients | Flow | Esophagus | Cirrhosis | Alteration of flow | Nuclear magnetic resonance | NMR
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2011, Volume 29, Issue 5, pp. 1090 - 1093
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 10/2012, Volume 11, Issue 10, pp. 2284 - 2293
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2012, Volume 30, Issue 1, pp. 376 - 381
Purpose The only drug that improves survival in hepatocellular carcinoma is sorafenib. FOLFOX-4 regimen is safe and widely used in patients with colorectal... 
5-fluorouracil | Chemotherapy | Oxaliplatin | Medicine & Public Health | Cirrhotic patients | Oncology | Hepatocellular carcinoma | Pharmacology/Toxicology | Liver transplantation | ONCOLOGY | PHARMACOLOGY & PHARMACY | SORAFENIB | GEMCITABINE PLUS OXALIPLATIN | Leucovorin - administration & dosage | Carcinoma, Hepatocellular - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Liver Transplantation - adverse effects | Humans | Middle Aged | Liver Cirrhosis - mortality | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Liver Neoplasms - mortality | Feasibility Studies | Liver Neoplasms - etiology | Organoplatinum Compounds - administration & dosage | Carcinoma, Hepatocellular - drug therapy | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Retrospective Studies | Chemotherapy, Adjuvant | Drug Administration Schedule | Liver Cirrhosis - complications | Liver Neoplasms - drug therapy | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Liver Transplantation - mortality | Treatment Outcome | Disease-Free Survival | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Organoplatinum Compounds - adverse effects | Paris | Complications and side effects | Care and treatment | Patient outcomes | Liver | Dosage and administration | Leucovorin | Transplantation | Hepatoma | Health aspects | Fluorouracil | Studies | Liver cancer | Pharmacology | Transplants & implants | Liver cirrhosis | Index Medicus
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 12/2019, Volume 94, Issue 12, pp. 2591 - 2593
Journal Article
Journal Article